DiMasiJA, GrabowskiHG, HansenRW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ, 2016; 47:20–33; doi: 10.1016/j.jhealeco.2016.01.012
2.
CrookeST, BakerBF, CrookeRM, et al.Antisense technology: An overview and prospectus. Nat Rev Drug Discov, 2021; 20(6):427–453; doi: 10.1038/s41573-021-00162-z
3.
(CDER) USDoHaHSFaDACfDEaR. IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations Guidance for Sponsor-Investigators. Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002; 2021.
4.
(CDER) USDoHaHSFaDACfDEaR. Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators. 2021.
5.
(CDER) USDoHaHSFaDACfDEaR. IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators. 2021.
6.
(CDER) USDoHaHSFaDACfDEaR. IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations Guidance for Sponsor-Investigators. 2021.
